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Abstract
Objectives—Obesity and diabetes are strong risk factors that drive the development of type I
endometrial cancers. Recent epidemiological evidence suggests that metformin may lower cancer
risk and reduce rates of cancer deaths among diabetic patients. In order to better understand
metformin's anti-tumorigenic potential, our goal was to assess the effect of metformin on proliferation
and expression of key targets of metformin cell signaling in endometrial cancer cell lines.
Methods—The endometrial cancer cell lines, ECC-1 and Ishikawa, were used. Cell proliferation
was assessed after exposure to metformin. Cell cycle progression was evaluated by flow cytometry.
Apoptosis was assessed by ELISA for caspase-3 activity. hTERT expression was determined by real-
time RT-PCR. Western immunoblotting was performed to determine the expression of the
downstream targets of metformin.
Results—Metformin potently inhibited growth in a dose-dependent manner in both cell lines
(IC50 of 1 mM). Treatment with metformin resulted in G1 arrest, induction of apoptosis and decreased
hTERT expression. Western immunoblot analysis demonstrated that metformin induced
phosphorylation of AMPK, its immediate downstream mediator, within 24 hours of exposure. In
parallel, treatment with metformin decreased phosphorylation of S6 protein, a key target of the mTOR
pathway.
Conclusions—We find that metformin is a potent inhibitor of cell proliferation in endometrial
cancer cell lines. This effect is partially mediated through AMPK activation and subsequent inhibition
of the mTOR pathway. This work should provide the scientific foundation for future investigation
of metformin as a strategy for endometrial cancer prevention and treatment.
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Endometrial cancer is the fourth most common cancer among women in the United States and
has been increasing in frequency secondary to an aging female population and changes in
dietary and hormonal factors, with obesity being a major culprit [1,2]. It is estimated that 40,100
new cases will be diagnosed in 2008, and 7,470 women will succumb to this disease [3].
Therefore, there is great interest in identifying novel ways to treat and prevent this disease.
Obesity, diabetes and insulin resistance are strong risk factors that drive the development of
the more common type I endometrial cancers. Unfortunately, obesity is not only a risk factor
for developing endometrial cancer, but it is associated with an increased risk of death [4-6].
Obese women with endometrial cancer have a 6.25 increased risk of death from this disease
as compared to their non-obese counterparts [5]. Metformin (dimethylbiguanide) is a biguanide
drug that is widely used as the first line pharmacologic treatment of type II diabetes after
patients have failed diet and exercise modification. There is recent epidemiological evidence
to suggest that metformin use lowers cancer risk and reduces the rate of cancer deaths among
diabetic patients as compared to sulfonylureas or insulin use [7,8]. It is unknown whether the
underlying mechanism behind metformin's potential anti-neoplastic effects are related to the
systemic action of this drug, by reducing circulating insulin levels, and/or a direct action on
cancer cells.
Metformin is commonly thought of as an insulin sensitizer because it enhances signaling
through the insulin receptor (IR), leading to an improvement in insulin resistance, followed by
a reduction in circulating insulin levels. More recently, evidence suggests that metformin's key
target of action is the inhibition of hepatic gluconeogenesis [9], resulting in a secondary decline
in insulin levels. Metformin has become the cornerstone of treatment for women with
polycystic ovarian syndrome (PCOS), a disease characterized by elevated circulating androgen
levels, chronic anovulation, obesity and frequently insulin resistance [10]. Metformin has been
found to improve the reproductive abnormalities in women with PCOS, restoring ovulation
and improving fertility [10]. Women with PCOS who respond to metformin have generally a
decrease in circulating insulin and androgen levels, suggesting that both hyperinsulinemia and
hyperandrogenemia contribute to the clinical manifestation of this syndrome which is
associated with an increased risk of endometrial cancer. Despite its known benefit in the
treatment of women with PCOS, the effect of metformin on the endometrium has yet to be
explored.
Although the molecular mechanism of metformin has been well-studied in tissues such as liver,
muscle and fat, very little is known about its effects on epithelial tissues. Metformin exerts its
beneficial effects through activation of the AMP-activated protein kinase (AMPK) in muscle,
adipose tissue and liver [11]. AMPK is a heterotrimeric serine/threonine protein kinase
complex, comprising a catalytic α-subunit and regulatory β and γ subunits [11]. AMPK
regulates energy metabolism and is activated in response to cellular stresses that deplete cellular
energy levels and increase the AMP/ATP ratio [11]. AMPK uniquely detects cellular energy
and ensures that cell division only proceeds if there are sufficient metabolic resources to support
proliferation. Once activated, AMPK restores cellular energy levels by stimulating catabolic
pathways, such as glucose uptake, glycolysis and fatty acid oxidation and halting ATP-
consuming processes such as fatty acid, cholesterol and protein synthesis. LKB1 is the kinase
responsible for phosphorylating and activating AMPK [9]. Interestingly, LKB1 encodes for a
tumor suppressor gene that is lost in Peutz-Jeghers syndrome, a disease characterized by
colonic polyps and a predisposition to epithelial malignancies such as breast, colon and lung
cancer [12]. Loss of LKB1 expression has also been documented in up to 65% of human
endometrial cancers and has been correlated with tumors of higher grade and more advanced
stage [13,14].
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Activation of AMPK through LKB1 leads to regulation of multiple signaling pathways
involved in the control of cellular proliferation, including the mTOR pathway. It is thought
that AMPK mediates its effect on cell growth through inhibition of mTOR via phosphorylation
of the tuberous sclerosis complex (TSC2), a subunit of the larger TSC1/TSC2 (hamartin/
tuberin) complex that negatively regulates mTOR signaling. Alterations in the mTOR pathway
have previously been implicated in endometrial cancer carcinogenesis. PTEN is a negative
regulator of this pathway, and loss of PTEN expression is one of the most prevalent molecular
abnormalities associated with endometrial cancers, occurring in up to 83% of type I endometrial
cancers [15-17]. The mTOR pathway is thought to be a promising target for endometrial cancer
treatment, with many mTOR inhibitors already in clinical trials for this disease.
Given the relationship between the AMPK and mTOR signaling pathways, we hypothesize
that metformin may behave like a novel mTOR inhibitor, with important chemotherapeutic
implications for endometrial cancer, a disease which is strongly influenced by obesity and
insulin resistance. Thus, in order to better understand metformin's anti-tumorigenic potential,
our goal was to assess the in vitro effect of metformin on proliferation, apoptosis and expression
of key targets of metformin cell signaling in endometrial cancer cell lines.
Materials and Methods
Cell Culture and Reagents
Two endometrial cancer cell lines, ECC-1 and Ishikawa, were used for these experiments.
Ishikawa cells were grown in MEM supplemented with 5% fetal bovine serum, 300 mM L-
glutamine, 5 μg/ml bovine insulin, 10,000 units/ml penicillin, and 10,000 μg/ml streptomycin
under 5% CO2. ECC-1 cells were maintained in RPMI 1640 containing 5% fetal bovine serum,
300 mM L-glutamine, 5 μg/ml bovine insulin, 10,000 units/ml penicillin, and 10,000 μg/ml
streptomycin under 5% CO2. Metformin, MTT (3-(,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) dye, RNase A, anti-PTEN antibody and anti-β-actin antibody
were purchased from Sigma (St. Louis, MO). The anti-phospho-AMPK, anti-pan-AMPK, anti-
phospho-S6, anti-pan-S6 antibodies and the caspase-3 ELISA kit were purchased from Cell
Signaling (Beverly, MA). Enhanced chemiluminescence Western blotting detection reagents
were purchased from Amersham (Arlington Heights, IL). All other chemicals were purchased
from Sigma.
Cell Proliferation Assays
The effects of metformin treatment on cell proliferation was examined by MTT assay. The
ECC-1 and Ishikawa cells were plated and grown in 96-well plates at a concentration of 6000
cells/μL and 8000 cells/μL respectively for 24 hours. Cells were then treated with varying doses
of metformin for 24-72 hours. Viable cell densities were determined by metabolic conversion
of the dye MTT. MTT (5 mg/ml) was added to the 96 well plates at 10 μL/well, and the plates
were then incubated for an additional hour. The MTT reaction was terminated by the addition
of 100 μl of DMSO. Subsequently, the MTT assay results were read by measuring absorption
at 595 nm. The effect of metformin was calculated as a percentage of control cell growth
obtained from PBS treated cells grown in the same 96 well plates. Each experiment was
performed in triplicate and repeated three times to assess for consistency of results.
Flow Cytometry
To evaluate the mechanism of growth inhibition by metformin, the cell cycle profile was
analyzed after treatment with metformin. Both cell lines were plated at 2.5 × 105 cells/well in
6 well plates in their corresponding media for 24 hours. Subsequently, the cells were starved
overnight and then treated with 15% serum and metformin at varying concentrations for 36
hours. Cells were collected, washed with PBS, fixed in a 90% methanol solution and then
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stored at -20 °C until flow cytometric analysis was performed. On the day of analysis, cells
were washed and centrifuged using cold PBS, suspended in 100μL PBS and 10uL of RNase
A solution (250 μg/ml) followed by incubation for 30 minutes at 37°C. After incubation, 110
μL of PI stain (100 μg/ml) were added to each tube and incubated at 4°C for at least 30 minutes
prior to analysis. Flow cytometric analysis was performed on a CyAn machine (Beckman
Coulter, Miami, FL). ModFit (Verity Software House, Topsham, ME) was utilized for the
analysis to control for dead cells and debris. All experiments were performed in triplicate and
repeated twice to assess for consistency of response.
Apoptosis Assay
To evaluate the mechanism of growth inhibition by metformin, the induction of apoptosis was
analyzed after exposure to metformin. Both cell lines were cultured in 6 well plates to
concentrations of 2-4 × 105 cells/well for 24 hours and then treated with metformin at indicated
doses in 0.5% stripped serum for an additional 24 hours. ELISA analysis with a Caspase-3 kit
was performed according to manufacturer instructions. Briefly, the cells were lysed and protein
concentrations measured to confirm equal loading onto an ELISA plate. Reagents were added
as described by the manufacturer, and the ELISA plate was read by measuring absorption at
450 nm. All experiments were performed in triplicate and repeated twice to assess for
consistency of response.
Real-time RT-PCR
The hTERT gene encodes the catalytic subunit of telomerase. hTERT expression is the rate-
limiting determinant of the enzymatic activity of human telomerase and is thought to be a
sensitive marker of telomerase function and cell proliferation. Thus, we examined the effect
of metformin treatment on hTERT expression in the endometrial cancer cell lines by real-time
RT-PCR. Total RNA was extracted using the AIQshredder kit (Qiagen, Valencia, CA) and
further purified by the RNeasy Mini-kit (Qiagen, Valencia, CA). The reverse transcription and
PCR reactions were performed using the TaqMan Gold one-step RT-PCR kit in the ABI Prism
7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Reverse
transcription was carried out at 48°C for 30 min. The PCR conditions consisted of a 10 min
step at 95°C, 40 cycles at 95°C for 15 sec each and 1 min at 65°C. A housekeeping control
gene acidic ribosomal phosphoprotein P0 (RPLP0, also known as 36B4) was used as an internal
control to correct for differences in the amount of RNA in each sample. Primers and fluorogenic
probes for hTERT and RPLP0 have been described previously [18]. The standard curve for
hTERT was generated by using dilutions of a known amount of cRNA synthesized by in
vitro transcription of a cloned fragment. The normalized level of hTERT in each sample was
estimated by a ratio of the hTERT level to the RPLP0 level, as described previously [18]. Each
experiment was performed in triplicate and repeated twice to assess for consistency of results.
Western Immunoblotting
To investigate the mechanisms underlying the anti-proliferative effect of metformin, we
characterized the effect of metformin on relevant cell signaling targets, including AMPK and
phosphorylated S6. The PTEN status of these two cell lines was also characterized. The
Ishikawa and ECC-1 cells were plated at 2 × 105 cells/well in 6 well plates in their
corresponding media and then treated for 16 hours with metformin in 0.5% stripped serum.
Cell lysates were prepared in RIPA buffer (1% NP40, 0.5 sodium deoxycholate and 0.1% SDS).
Equal amounts of protein were separated by gel electrophoresis and transferred onto a
nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk and then
incubated with a 1:1000 dilution of primary antibody overnight at 4°C. The membrane was
then washed and incubated with a secondary peroxidase-conjugated antibody for 1 hour after
washing. Antibody binding was detected using an enhanced chemiluminescence detection
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system (GE Healthcare Life Sciences, Piscataway, NJ). After developing, the membrane was
stripped and re-probed using antibody against β-actin and either pan-S6 or pan-AMPK to
confirm equal loading. Each experiment was repeated three times to assess for consistency of
results.
Statistical Analysis
Results for experiments were normalized to the mean of the control and analyzed using the
student t-test. Differences were considered significant if the p value was less than 0.05 (p<0.05)
with a confidence interval of 95%. STATA software (StataCorp, College Station, TX) was
used to perform statistical analyses.
Results
Sensitivity of Endometrial Cancer Cells to Metformin
We examined the effect of metformin on proliferation in two endometrial cancer cell lines. As
shown in Figure 1, metformin potently inhibited growth in a dose-dependent manner in both
endometrial cancer cell lines at 24-72 hours (p=0.0198-0.0348 for ECC-1 and p=0.0056-0.0166
for Ishikawa). The mean IC50 value for each of these cell lines was approximately 1 mM.
Effect of Metformin on Cell Cycle and Apoptosis
To evaluate the mechanism of growth inhibition by metformin, the cell cycle profile and
induction of apoptosis was analyzed after treatment with metformin. As expected, serum
stimulation resulted in transition of cells from G1 to S phase by 24 hr, with a concomitant
decrease in G1 phase. Metformin significantly blocked serum-induced entry to S phase,
resulting in G1 cell cycle arrest (Figure 2). This effect was seen in both endometrial cancer cell
lines and appeared to be dose-dependent (p= 0.0165-0.0482 for ECC-1 and p=0.0239-0.0586
for Ishikawa). The percent change ranged from 13.4 – 14.1%, depending on the cell line.
An apoptosis assay using an antibody to caspase-3 was performed after exposure to metformin.
Caspases are a family of cysteine proteases that act in a cascade to trigger apoptosis. Caspase-9
is an initiator caspase that is thought to activate the effector caspases (caspase-3 and -6)
involved in actual cell disassembly. Caspase-3 is considered to be a specific marker for
epithelial apoptosis. Metformin induced apoptosis but only at high doses of treatment (2-5
mM) as demonstrated by increased caspase-3 activity (p=0.008-0.0032 for ECC-1 and
p=0.0108-0.0218 for Ishikawa) (Figure 3). Lower doses of metformin had little effect on
caspase-3 activity.
These results suggest that metformin predominantly inhibits cell growth via cell cycle arrest
and not by induction of apoptosis in these endometrial cancer cell lines. Induction of apoptosis
may contribute to metformin's anti-proliferative effect but only in the presence of high
concentrations of this drug.
Effect of Metformin on hTERT mRNA Level
The maintenance of telomere length via the expression of telomerase is vital to the ability of
cancer cells to remain proliferative. hTERT expression is the rate-limiting determinant of the
enzymatic activity of human telomerase; and thus, real time RT-PCR was used to quantify
hTERT mRNA expression in the endometrial cancer cell lines. Treatment with metformin
decreased hTERT mRNA expression in a dose-dependent manner in both cell lines within 24
hours (p=0.004-0.05 for ECC-1 and p=0.0008-0.0255 for Ishikawa) (Figure 4) and 48 hours
(data not shown). This data suggests that metformin may inhibit telomerase activity by rapidly
decreasing hTERT mRNA levels.
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Effect of Metformin on the mTOR Pathway
To investigate the mechanisms underlying the anti-proliferative effect of metformin, we
characterized the effect of metformin on relevant cell signaling targets. In both endometrial
cancer cell lines, Western immunoblot analysis demonstrated that metformin induced
phosphorylation in a dose-dependent fashion of AMPK, its immediate downstream mediator,
within 16 hours of exposure (Figure 5A & 5B). Previous studies suggest that p70S6K is a
downstream target of the mTOR pathway [19]. p70S6K kinase directly phosphorylates the 40S
ribosomal protein S6, which results in enhanced translation of proteins that contain a
polypyrimidine tract in the 5′-untranslated region [19]. Therefore, we studied the effect of
metformin on the phosphorylation of the S6 ribosomal protein in both cell lines. Within 16
hours of treatment, metformin dramatically decreased the phosphorylation of S6 (Figure 5C
& 5D). Expression of pan-AMPK and pan-S6 were not affected by metformin. This suggests
that metformin may exert its anti-proliferative effect through activation of AMPK and
subsequent decreased phosphorylation of the S6 protein, resulting in inhibition of the mTOR
pathway.
The expression of wild-type PTEN in the endometrial cancer cell lines was determined by
Western immunoblotting (Figure 5E). Loss of PTEN expression is thought to enhance
sensitivity of tumor cells to the effects of mTOR inhibitors [20-23]. The Ishikawa and ECC-1
cell lines were both strongly positive for PTEN. Thus, we were unable to assess the effect of
PTEN status on response to treatment with metformin. However, we can conclude that PTEN
does not need to be absent for metformin to be a potent inhibitor of cell proliferation.
Discussion
We have demonstrated that metformin is a potent inhibitor of cell proliferation in two
endometrial cancer cell lines, predominantly through G1 cell cycle arrest. Metformin was
capable of inducing apoptosis but only at high concentrations of treatment. In addition,
metformin suppressed hTERT mRNA expression in both of these cell lines. Treatment with
metformin resulted in activation of AMPK, its immediate downstream target, followed by
decreased phosphorylation of S6, signifying inhibition of the mTOR pathway. These findings
suggest that metformin may function as a novel mTOR inhibitor and emerge as a targeted
chemotherapeutic strategy for both the treatment and prevention of endometrial cancer.
Although metformin has been shown to inhibit proliferation in vitro in breast, prostate, colon
and ovarian cancer cell lines [24-26], this is the first time that this has been demonstrated for
endometrial cancer, which of all of these cancers is the one most impacted by obesity and
insulin resistance.
Metformin's immediate downstream target is AMPK, and AMPK activation leads to regulation
of multiple downstream pathways involved in the control of cellular proliferation, including
the mTOR pathway (Figure 6). AMPK mediates its effect on cell growth through inhibition of
mTOR via phosphorylation of the tuberous sclerosis complex (TSC2), a subunit of the larger
TSC1/TSC2 (hamartin/tuberin) complex that negatively regulates mTOR signaling. In breast
cancer cell lines, metformin-mediated AMPK activation was shown to decrease cell growth
through inhibition of mTOR and a decrease in phosphorylation of its downstream targets, S6
and eIF-4E-binding proteins [25,27]. This ultimately resulted in a significant reduction in
initiation of translation. Similar results have been found in prostate, colon and ovarian cancer
cell lines [24,26] and confirmed by our findings in endometrial cancer cell lines (Figure 5).
AMPK activation is thought to be a possible therapeutic target for cancers with activated Akt
signaling, since AMPK inhibits mTOR signaling downstream of Akt. Given the high
prevalence of PTEN mutations in endometrial cancer which leads to constitutive Akt
expression, AMPK activation through metformin may be a particularly compelling anti-cancer
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strategy for this disease. Both of the endometrial cancer cell lines examined in these studies
expressed wild-type PTEN, demonstrating that PTEN does not need to be absent for metformin
to be an effective inhibitor of cell proliferation. Other researchers have shown that loss of PTEN
function in PTEN-null cancer cells confers increased sensitivity to mTOR inhibition by
rapamycin [20-23]. Our future plans include further evaluation of PTEN status on response to
treatment with metformin through either comparison with other PTEN-null endometrial cancer
cell lines or selective silencing of PTEN via small interfering RNA (siRNA). However, given
that both wild-type PTEN and PTEN-null tumors may potentially respond to metformin
treatment, this would increase the generalizability of this therapy for endometrial cancer
patients and may also have a bearing on type II endometrial cancers, which less frequently
have PTEN mutations.
In addition, we have demonstrated that metformin suppressed proliferation in the endometrial
cancer cell lines via G1 cell cycle arrest (Figure 2). This result is not surprising, given that
mTOR inhibitors have also been shown to arrest cells in the G1 phase in a number of different
cancer cell types, including our work in endometrial, ovarian and cervical cancer cell lines
[28,29]. It is controversial whether metformin may also induce apoptosis. In the endometrial
cancer cells, metformin was able to induce apoptosis but only at high concentrations of
treatment (Figure 3), suggesting that cell cycle arrest as opposed to cell death is most likely
the major contributor to metformin's anti-proliferative effect. In contrast, metformin failed to
induce apoptosis in prostate and breast cancer cell lines at similar doses of treatment but did
block cell cycle progression in G1 phase [30,31]. However, metformin was found to induce
apoptosis in vitro in colon cancer cells but only in those cells that lacked the tumor suppressor
p53 [32]. Both endometrial cancer cell lines used in this work express wild-type p53 (data not
shown); and thus, it is possible that metformin may selectively induce apoptosis at more
physiologic doses in p53-deficient endometrial cancer cells. This may have possible
implications for type II endometrial cancers which more often have mutated p53.
In most normal somatic cell types, telomerase activity is usually undetectable; however, the
endometrium is one exception [33]. It is thought that telomerase plays a critical role in the
ability of normal endometrium to repeatedly proliferate from the onset of menarche to
menopause. Furthermore, activation of telomerase has also been implicated as a fundamental
step in cellular immortality and oncogenesis in many cancers [33], including endometrial
cancers [34,35]. Ninety percent of endometrial cancers have been found to express telomerase.
Telomerase is comprised of an RNA template (hTR) and the catalytic protein hTERT which
has reverse transcriptase activity. hTERT is considered to be the rate-limiting factor in the
formation of functional telomerase. In this study, metformin was found to decrease hTERT
expression in the endometrial cancer cell lines, which to our knowledge is the first time
metformin has been linked to regulation of telomerase activity.
Regulation of hTERT transcription during the cell cycle is controversial with some
investigators reporting high activity in S phase and undetectable levels in G2-M phase and
others demonstrating no change throughout the cell cycle [36,37]. If hTERT transcription is
cell cycle dependent and non-cycling cells do not express hTERT, then the effect of metformin
on hTERT expression may potentially occur as an indirect consequence of cell cycle arrest
rather than a direct effect on hTERT transcription. We have previously demonstrated that the
mTOR inhibitor, rapamycin, profoundly suppresses telomerase activity via inhibition of
hTERT mRNA expression in endometrial, ovarian and cervical cancer cell lines [28,29].
However, in cell lines that were resistant to rapamycin's anti-proliferative effects and failed to
undergo G1 arrest, rapamycin still decreased hTERT expression, suggesting that rapamycin's
effect on regulation of hTERT expression was independent of its ability to induce cell cycle
arrest [29]. Thus, we concluded that rapamycin may regulate hTERT mRNA expression
through an alternative pathway downstream from mTOR, unrelated to cell cycle control. This
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concept may also apply to metformin, given its known interaction with the mTOR pathway,
but this remains to be proven.
We should acknowledge that the doses of metformin (0.01 – 5 mM) used in these in vitro
studies are supratherapeutic compared to those doses used in diabetic patients. This has been
a previously raised criticism of similar work in other cancer cell types, such as breast, prostate
and colon cancer cell lines [24-27]. The maximum recommended clinical metformin dose is
2250 mg/day. In clinical pharmacokinetic studies, therapeutic levels measured in healthy
volunteers range from 0.5 to 2.0 mg/L (peak plasma levels 0.6 to 1.8 ug/mL), and other
investigators have calculated 20 uM as a clinically equivalent dose in vitro [38,39]. However,
it is important to consider that cells in culture are grown under hyperglycemic conditions in an
environment of overabundant nutrients. Tissue culture media alone contains high
concentrations of glucose, and 5-10% fetal bovine serum is typically added, resulting in
excessive growth stimulation. This, of course, is an inherent limitation to in vitro studies using
cell lines and may be a viable explanation for why higher doses are needed to see the effects
of metformin in cell culture than what is typically used in diabetic patients.
Metformin has also been shown to accumulate in tissues at higher concentrations than in blood,
suggesting that increased concentrations of metformin may be achieved in target organs at
lower, more pharmacologic doses [40]. Thus, despite the discrepancy in dosing between these
in vitro studies and clinical metformin use for diabetic treatment, metformin's anti-tumorigenic
potential more than deserves a thorough assessment for endometrial cancer prevention and
treatment. These issues in regards to dosing may be more accurately addressed in vivo using
animal models prior to validation in clinical trials, which is one of our future research goals.
A well-established phenomenon of tumor cells is a shift in glucose metabolism from oxidative
phosphorylation to aerobic glycolysis, termed the “Warburg” effect [41]. The PI3K/Akt/mTOR
pathway is known to play a crucial role in both growth control and glucose metabolism. PI3K
signaling through Akt can modulate glucose transporter expression, stimulate glucose capture
by hexokinase and increase phosphofructokinase activity [41]. In support of this theory,
response to anti-cancer therapies, such as tyrosine kinase inhibitors, can often be predicted by
the decreased metabolism of glucose by tumors as measured by FDG-PET [41]. Thus, it is
intriguing to postulate that an additional anti-tumorigenic benefit of metformin may be through
regulation of glucose uptake and utilization by endometrial cancer cells. We plan to investigate
this relationship between metformin cell signaling and glucose metabolism as part of our future
work.
Since obesity and diabetes have been linked to an increased risk of mortality from endometrial
cancer, patients after diagnosis are strongly encouraged to make lifestyle changes such as diet,
weight reduction and exercise. Unfortunately, these lifestyle changes are challenging for
patients, and pharmacologic intervention through metformin may be an innovative
chemotherapeutic strategy to both treat endometrial cancer and improve outcomes for these
“high risk” women by impacting insulin resistance. Furthermore, we postulate that
maintenance therapy with metformin after endometrial cancer diagnosis and treatment may
prevent recurrences in this unique patient population where obesity and diabetes are such
predominant risk factors. This concept is even more intriguing given that metformin has been
shown to improve outcomes in diabetic cancer patients as compared to sulfonylureas or insulin
use [7,8]. Thus, metformin may emerge as an effective targeted therapy in the treatment and
long-term management of endometrial cancer, with the additional benefits of low cost, oral
route of administration, proven safety and very little toxicity. We hope that this work will begin
to provide the scientific foundation for future clinical trials of metformin for endometrial cancer
treatment and ultimately, prevention.
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Effect of metformin on proliferation of endometrial carcinoma cells. Ishikawa and ECC-1 cells
were cultured in the presence of varying concentrations of metformin for 72 hours. Relative
growth of cells were determined by MTT. The results are shown as the mean ± SE of triplicate
samples and are representative of three independent experiments. (* indicates statistically
significant difference)
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Metformin inhibited cell cycle progression by arrest in G1 phase. The endometrial cancer cell
lines, ECC-1 (A) and Ishikawa (B), were starved overnight and then stimulated with 15% serum
and metformin at the noted concentrations for 36 hours. Cell cycle analysis was performed by
flow cytometry. Results shown are representative of two independent experiments. (* indicates
statistically significant difference)
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Metformin induced apoptosis but only at high concentrations. The endometrial cancer cell lines
(A) ECC-1 and (B) Ishikawa were grown for 24 hours and then treated with metformin at the
indicated concentrations for an additional 24 hours. Apoptosis was assessed using an antibody
to caspase-3. The results are shown as the mean +/- SD and are representative of two
independent experiments. (* indicates statistically significant difference)
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Metformin decreased hTERT mRNA expression in a dose-dependent manner in the (A) ECC-1
and (B) Ishikawa cell lines. Both cell lines were cultured for 24 hours and then treated with
the indicated concentrations of metformin for an additional 24 hours. hTERT expression was
determined by real-time RT-PCR. The results are shown as the mean ± SE of two independent
experiments. (* indicates statistically significant difference)
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In both endometrial cancer cell Lines ECC-1 (A & C) and Ishikawa (B & D), metformin
increased phosphorylation of AMPK and decreased phosphorylation of S6 in a dose-dependent
manner within 16 hours of exposure as determined by Western immunoblotting. Little effect
was seen on total AMPK (Pan-AMPK) or total S6 (Pan-S6). Both cell lines expressed wild-
type PTEN (E).
Cantrell et al. Page 16














Interaction between the metformin and mTOR pathways.
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